XOMA Co. (NASDAQ:XOMA) CEO Sells $655,335.95 in Stock

by · The Cerbat Gem

XOMA Co. (NASDAQ:XOMA – Get Free Report) CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

XOMA Stock Up 1.1 %

Shares of XOMA stock opened at $30.21 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company’s fifty day simple moving average is $28.72 and its two-hundred day simple moving average is $26.89. XOMA Co. has a 12-month low of $14.33 and a 12-month high of $33.78.

XOMA (NASDAQ:XOMA – Get Free Report) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $11.09 million during the quarter, compared to analysts’ expectations of $8.37 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, analysts expect that XOMA Co. will post -0.79 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on XOMA shares. StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $117.00 price objective on shares of XOMA in a research report on Wednesday, October 23rd.

Get Our Latest Stock Analysis on XOMA

Institutional Trading of XOMA

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA in the 1st quarter worth about $212,000. Rhumbline Advisers grew its position in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares during the period. Barclays PLC grew its position in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the period. Finally, Ellsworth Advisors LLC purchased a new stake in shares of XOMA in the 3rd quarter worth about $516,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Further Reading